Integrated BioPharma, Inc. To Supply BJ's Wholesale Club With Its Propriety Nutraceutical Beverage Line

HILLSIDE, N.J., March 8 /PRNewswire-FirstCall/ -- AgroLabs, Inc., a wholly owned subsidiary of Integrated BioPharma, Inc. , agreed with BJ's Wholesale Club to supply all 163 BJ's Wholesale Club stores with it Naturally Noni and Naturally Pomegranate liquid dietary supplements. BJ's Wholesale Club is a leading warehouse club operator in the eastern United States.

E. Gerald Kay, Chief Executive Officer of INB, said, "AgroLabs continues to expand the availability of its Naturally Noni and Naturally Pomegranate liquid healthful nutritional products. These products will begin making their way onto BJ's shelves immediately." Mr. Kay added, "Our AgroLabs subsidiary is very focused on building the Company's name recognition as a leading provider of healthful nutritional products."

AgroLabs, Inc. distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most recently, Acai Extreme Energy. These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. Additional information on AgroLabs and its products can be obtained from its website at http://www.agrolabs.com or by calling (817) 410-2140.

About Integrated BioPharma Inc (INB)

Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at http://www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

Integrated BioPharma, Inc.

CONTACT: Dina Masi, CFO of Integrated BioPharma Inc, +1-888-319-6962, ord.masi@ibiopharma.com

Back to news